Crossmark

CT-01 Phase IB study of IMMU-115 (humanised ANTI-CD74 antibody) targeting antigen presenting cells in patients with systemic lupus erythematosus (SLE)

Crossref DOI link: https://doi.org/10.1136/lupus-2016-000179.73

Published Online: 2016-08-31

Published Print: 2016-09

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Wallace, Daniel J

Wegener, William A

Horne, Heather

Goldenberg, David M
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct01845740 at ClinicalTrials.gov

Documents that mention this clinical trial

CT-01 Phase IB study of IMMU-115 (humanised ANTI-CD74 antibody) targeting antigen presenting cells in patients with systemic lupus erythematosus (SLE)
https://doi.org/10.1136/lupus-2016-000179.73

Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)
https://doi.org/10.1136/annrheumdis-2020-219803

Document is current

Any future updates will be listed below